{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:22:14Z","timestamp":1788391334453,"version":"build-2803163510"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004319","name":"PFIZER","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>After the implementation of pneumococcal conjugate vaccines (PCVs), besides the decrease of invasive pneumococcal disease (IPD), the clinical spectrum of the remaining cases changed, with many differences among serotypes. This study aimed to describe the clinical profile of IPD and the serotype distribution 15\u00a0years after PCV13 implementation and before the implementation of third-generation PCVs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>From 2017 to 2022, 128 French pediatric wards prospectively reported IPDs in children. Data were collected on demographics and clinical data, underlying conditions increasing the risk of IPD and outcome. Four clinical entities were considered: meningitis, bacteremia without source, bacteremic pneumonia, and other IPD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 931 IPD cases (median age of children: 19.2\u00a0months, Interquartile range (IQR): 7.7-52.5), meningitis accounted for 36.4%, followed by bacteremia without source (31.6%), bacteremic pneumonia (20.5%), and other IPDs (11.5%). Underlying conditions were reported in 21.5% of children. Death was reported in 4.8% of IPD cases and meningitis represented 51.1% of fatal cases. PCV13 serotypes, mainly 3, 19A, and 19F, still accounted for 15.0% of cases. PCV15 covered 6.2% more serotypes than did PCV13, whereas PCV20 covered 29.1% more serotypes than did PCV15. PCV20 non-PCV13 and PCV13 serotypes accounted for 33.3% and 11.1% of deaths, respectively. Serotype 24F ranked first and accounted for 16.4% of overall IPD cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>From 2017 to 2022, among 931 IPD cases, PCV20 non-PCV13 serotypes (35.0% of cases) were implicated in 33.3% of deaths. Serotype 24F ranked first in overall IPD cases but is not included in third-generation PCVs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpids\/piaf056","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T07:38:14Z","timestamp":1749541094000},"source":"Crossref","is-referenced-by-count":7,"title":["Pediatric Invasive Pneumococcal Disease Spectrum Before Third-Generation Pneumococcal Conjugate Vaccine Implementation"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-6360","authenticated-orcid":false,"given":"Corinne","family":"Levy","sequence":"first","affiliation":[{"name":"ACTIV, Association Clinique et Th\u00e9rapeutique Infantile du Val-de-Marne , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"AFPA, Association Fran\u00e7aise de P\u00e9diatrie Ambulatoire , 30400 Villeneuve les Avignons ,","place":["France"]},{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Cr\u00e9teil , 94000 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Estivaux","sequence":"additional","affiliation":[{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"Service de p\u00e9diatrie H\u00f4pital de Villeneuve Saint Georges , 94190 Villeneuve Saint Georges ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3043-2838","authenticated-orcid":false,"given":"Emmanuelle","family":"Varon","sequence":"additional","affiliation":[{"name":"ACTIV, Association Clinique et Th\u00e9rapeutique Infantile du Val-de-Marne , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"D\u00e9partement Recherche Innovation Information M\u00e9dicale, Centre National de R\u00e9f\u00e9rence des Pneumocoques, Centre Hospitalier Intercommunal de Cr\u00e9teil , 94000 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"B\u00e9chet","sequence":"additional","affiliation":[{"name":"ACTIV, Association Clinique et Th\u00e9rapeutique Infantile du Val-de-Marne , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"AFPA, Association Fran\u00e7aise de P\u00e9diatrie Ambulatoire , 30400 Villeneuve les Avignons ,","place":["France"]},{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Ouldali","sequence":"additional","affiliation":[{"name":"ACTIV, Association Clinique et Th\u00e9rapeutique Infantile du Val-de-Marne , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"AFPA, Association Fran\u00e7aise de P\u00e9diatrie Ambulatoire , 30400 Villeneuve les Avignons ,","place":["France"]},{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"Department of General Pediatrics, Pediatric Infectious Disease and Internal Medicine, Robert Debr\u00e9 University Hospital, Assistance Publique-H\u00f4pitaux de Paris , 75019 Paris ,","place":["France"]},{"name":"Infection, Antimicrobials, Modelling, Evolution (IAME), Inserm UMR 1137, 75006 Paris Cit\u00e9 University , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Hau","sequence":"additional","affiliation":[{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"Service de P\u00e9diatrie, Centre Hospitalier Intercommunal de Cr\u00e9teil , 94000 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Cohen","sequence":"additional","affiliation":[{"name":"ACTIV, Association Clinique et Th\u00e9rapeutique Infantile du Val-de-Marne , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"AFPA, Association Fran\u00e7aise de P\u00e9diatrie Ambulatoire , 30400 Villeneuve les Avignons ,","place":["France"]},{"name":"GPIP, Groupe de Pathologie Infectieuse P\u00e9diatrique , 75000 Paris ,","place":["France"]},{"name":"Universit\u00e9 Paris Est, IMRB-GRC GEMINI , 94000 Cr\u00e9teil ,","place":["France"]},{"name":"Clinical Research Center (CRC), Centre Hospitalier Intercommunal de Cr\u00e9teil , 94000 Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025081218183344000_ref1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-063039","article-title":"Invasive pneumococcal disease after 2 decades of pneumococcal conjugate vaccine use","volume":"153","author":"Yildirim","year":"2024","journal-title":"Pediatrics"},{"key":"2025081218183344000_ref2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/cid\/ciz221","article-title":"Changes in invasive pneumococcal disease spectrum after 13-valent pneumococcal conjugate vaccine implementation","volume":"70","author":"Levy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025081218183344000_ref3","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1016\/j.vaccine.2017.05.059","article-title":"Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: insights from Israeli surveillance studies","volume":"36","author":"Ben-Shimol","year":"2018","journal-title":"Vaccine"},{"key":"2025081218183344000_ref4","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1016\/j.vaccine.2024.04.061","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: an indirect cohort study","volume":"42","author":"Andrejko","year":"2024","journal-title":"Vaccine"},{"key":"2025081218183344000_ref5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14760584.2017.1320221","article-title":"Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries","volume":"16","author":"Cohen","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2025081218183344000_ref6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1473-3099(18)30349-9","article-title":"Incidence of paediatric pneumococcal meningitis and emergence of new serotypes: a time-series analysis of a 16-year French national survey","volume":"18","author":"Ouldali","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025081218183344000_ref7","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9040738","article-title":"Serotype distribution of remaining pneumococcal meningitis in the mature PCV10\/13 period: findings from the PSERENADE project","volume":"9","author":"Garcia","year":"2021","journal-title":"Microorganisms"},{"key":"2025081218183344000_ref8","doi-asserted-by":"publisher","first-page":"e735","DOI":"10.1016\/S2666-5247(22)00158-6","article-title":"Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study","volume":"3","author":"Lo","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025081218183344000_ref9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1086\/423820","article-title":"Temporal and geographic stability of the serogroup-specific invasive disease potential of Streptococcus pneumoniae in children","volume":"190","author":"Brueggemann","year":"2004","journal-title":"J Infect Dis"},{"key":"2025081218183344000_ref10","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jinf.2018.06.004","article-title":"The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis","volume":"77","author":"Balsells","year":"2018","journal-title":"J Inf Secur"},{"key":"2025081218183344000_ref11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.vaccine.2020.11.044","article-title":"In-depth analysis of pneumococcal serotypes in Belgian children (2015-2018): diversity, invasive disease potential, and antimicrobial susceptibility in carriage and disease","volume":"39","author":"Desmet","year":"2021","journal-title":"Vaccine"},{"key":"2025081218183344000_ref12","volume-title":"Mandatory Vaccination in France","author":"Ministry of Health and Prevention","year":"2022"},{"key":"2025081218183344000_ref13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/INF.0000000000004755","article-title":"High mortality due to pneumococcal meningitis in children with sickle cell disease: a French Multicenter Observational Study from 2001 to 2021","volume":"44","author":"Fafi","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"2025081218183344000_ref14","doi-asserted-by":"publisher","first-page":"2235238","DOI":"10.1080\/21645515.2023.2235238","article-title":"The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C","volume":"19","author":"Shi","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"2025081218183344000_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1560","article-title":"Immune responses to cross-reactive serotypes 6C and 15C after 20-valent pneumococcal conjugate vaccine in infants. Open forum","volume":"10","author":"Tamimi","year":"2023","journal-title":"Infect Dis"},{"key":"2025081218183344000_ref16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12090974","article-title":"Implications of cross-reactivity and cross-protection for pneumococcal vaccine development","volume":"12","author":"Feemster","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2025081218183344000_ref17","doi-asserted-by":"publisher","first-page":"6192","DOI":"10.1128\/IAI.71.11.6192-6198.2003","article-title":"Genetic basis for the structural difference between Streptococcus pneumoniae serotype 15B and 15C capsular polysaccharides","volume":"71","author":"van Selm","year":"2003","journal-title":"Infect Immun"},{"key":"2025081218183344000_ref18","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.vaccine.2022.12.054","article-title":"A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)","volume":"41","author":"Lupinacci","year":"2023","journal-title":"Vaccine"},{"key":"2025081218183344000_ref19","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.3201\/eid2808.220304","article-title":"Increased incidence of invasive pneumococcal disease among children after COVID-19 pandemic, England","volume":"28","author":"Bertran","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2025081218183344000_ref20","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12061020","article-title":"Dynamics of antibiotic resistance of Streptococcus pneumoniae in France: a pediatric prospective nasopharyngeal carriage study from 2001 to 2022","volume":"12","author":"Rybak","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2025081218183344000_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2024.104937","article-title":"The latest news in France before distribution of third-generation pneumococcal conjugate vaccines","volume":"54","author":"Cohen","year":"2024","journal-title":"Infect Dis Now"},{"key":"2025081218183344000_ref22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.14745\/ccdr.v50i12a04","article-title":"PCV13, PCV15 or PCV20: which vaccine is best for children in terms of immunogenicity?","volume":"50","author":"De Wals","year":"2024","journal-title":"CCDR"},{"key":"2025081218183344000_ref23","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/cid\/ciy920","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and meta-analysis of observational studies","volume":"68","author":"Sings","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025081218183344000_ref24","volume-title":"Prevenar 13 Summary of Product Characteristics","author":"European Medicines Agency"},{"key":"2025081218183344000_ref25","volume-title":"Annual Report of National Reference Center of Pneumococci","author":"Varon","year":"2023"},{"key":"2025081218183344000_ref26","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S2589-7500(23)00108-5","article-title":"Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS consortium","volume":"5","author":"Shaw","year":"2023","journal-title":"Lancet Digit Health"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piaf056\/63462610\/piaf056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/7\/piaf056\/63462610\/piaf056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/7\/piaf056\/63462610\/piaf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T22:18:39Z","timestamp":1755037119000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piaf056\/8159683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,8,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaf056","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,10]]},"article-number":"piaf056"}}